Diabetes
Refine Search
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Pharmaceutical
Effective July 1, uninsured people living with diabetes in the USA be able to obtain one or multiple Sanofi insulins from the French pharma major’s Insulins Valyou Savings Program with a valid prescription for a total of $35 for a 30-day supply. Previously, the program offered a 30-day supply of Sanofi insulins for $99. 30 June 2022
Pharmaceutical
German pharma major Bayer says that its Kerendia (finerenone) was recognized by the American Diabetes Association (ADA) Standards of Medical Care in Diabetes - 2022 with a new grade A recommendation for improving cardiovascular (CV) outcomes and reducing the risk of chronic kidney disease (CKD) progression in patients with CKD associated with type 2 diabetes (T2D). 29 June 2022
Pharmaceutical
With strong results from its SURPASS program for gastric inhibitory peptide/glucagon-like peptide-1 receptor (GIP/GLP-1) dual agonist Mounjaro (tirzepatide) for the treatment of type 2 diabetes (T2D), US pharma major Eli Lilly’s can expect Mounjaro to gain a significant share of the GLP-1 and wider T2D and obesity markets. 27 June 2022
Biotechnology
UK clinical-stage Zura Bio Limited, founded in January this year, and JATT Acquisition Corp, a publicly-traded US special purpose acquisition company (SPAC) formed for the purpose of acquiring or merging with one or more businesses, have entered into a definitive business combination agreement. 20 June 2022
Generics
Even as Germany’s Boehringer Ingelheim has obtained ad-interim injunctions against four Indian pharma companies that launched generic versions of the multinational's patent-protected drug linagliptin, Indian generic major Natco said that US firms Johnson & Johnson and Momenta Pharmaceuticals have filed a patent infringement lawsuit against it on two old patents associated with its glatiramer acetate injection. 13 June 2022
Pharmaceutical
Two analyses of the final US data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study show that Jardiance (empagliflozin) was associated with a reduction in risk of hospitalization for heart failure compared with two other classes of glucose-lowering therapies in adults with type 2 diabetes in routine care. 6 June 2022
Pharmaceutical
Danish diabetes care giant Novo Nordisk today announced positive headline results from the main phases of ONWARDS 1 (52 weeks) and ONWARDS 6 (26 weeks) Phase IIIa trials with once-weekly insulin icodec, edging the firm’s shares up 1.35 to 779.9 kroner. 3 June 2022
Generics
As Januvia/Janumet (sitagliptin), a Merck & Co drug, nears patent expiry, India's drug price regulator National Pharmaceutical Pricing Authority (NPPA) has fixed the prices of fixed-dose combinations of several anti-diabetic drugs with a 50% reduction on the patented component in a move set to increase the price war in India's $2.3 billion anti-diabetic drugs market. Howls of protest have followed the move, reports The Pharma Letter’s India correspondent. 30 May 2022
Biotechnology
The race to meet sudden, stratospheric demand for new anti-obesity meds is hotting up, but Novo Nordisk CEO Lars Fruergaard Jørgensen takes a collegiate approach. 26 May 2022
Pharmaceutical
Indiana, USA-based drugmaker Eli Lilly is making a major investment in its home state, with a $2.1 billion project to expand its manufacturing footprint. 26 May 2022
Generics
The US Food and Drug Administration yesterday published a new batch of product-specific guidances (PSGs). 20 May 2022
Pharmaceutical
The local subsidiary of Danish diabetes care giant Novo Nordisk, the sponsor of semaglutide (Ozempic) solution for injection pre-filled pen, notified the Therapeutic Goods Administration (TGA) of a shortage of both strengths of semaglutide (Ozempic) products due to an unexpected increase in consumer demand. 19 May 2022
Biotechnology
Hamburg-based biotech Evotec has launched a partnership in diabetes with Canadian company Sernova, a regenerative medicines specialist. 17 May 2022
Pharmaceutical
On Friday, the US Food and Drug Administration approved Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise. 14 May 2022
Pharmaceutical
The Himachal Pradesh High Court in India has restrained Macleods Pharmaceuticals, from infringing on the patent rights of Boehringer Ingelheim's linagliptin, marketed under the trade name Trulicity. 4 May 2022
Pharmaceutical
None of the global drugmakers operating in the Russian market has announced plans to terminate the supplies of their drugs to the country, according to recent statements by an official spokesman of the Russian healthcare regulator Roszdravnadzor, while some of them are even considering the increase of supplies, reports The Pharma Letter’s local correspondent. 4 May 2022
Biotechnology
A clinical hold on Phase I/II research into stem cell therapy VX-880 has left executives at Vertex Pharmaceuticals scratching their heads. 3 May 2022
Pharmaceutical
Danish diabetes care giant Novo Nordisk’s shares were up 6% in early trading, as the company released first-quarter 2022 financials that beat expectations and showed that sales increased 24% in Danish kroner and by 18% at constant exchange rates to 42.0 billion kroner ($6.09 billion). 29 April 2022
Pharmaceutical
Beating Wall Street estimates, Eli Lilly has posted strong first quarter 2022 financial results, with revenues up 15% at $7.8 billion. 28 April 2022
Pharmaceutical
Danish diabetes care giant Novo Nordisk today announced headline results from the ONWARDS 2 trial, a Phase IIIa, 26-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec versus insulin degludec in 526 people with type 2 diabetes switching from daily insulin. 28 April 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze